OIPE JC53
APR 19 2004
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:	Group Art Unit: 1645
Bar-Or et al.	Examiner:
Serial No.: 10/680,935	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Filed: October 2, 2003	
Atty. File No.: 4172-81	
For: "DIAGNOSIS AND MONITORING OF INFLAMMATION, ISCHEMIA AND APPENDICITIS"	

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA VA 22313-1450 ON APRIL 8, 2004.

SHERIDAN ROSS P.C.

BY: Constance Kbrott

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56, Applicants hereby submit this Supplemental Information Disclosure Statement with a copy of the documents identified on the enclosed PTO Form 1449. Applicants do not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicants that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: Gary J. Connell

Gary J. Connell
Registration No. 32,020
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: April 8, 2004

BEST AVAILABLE COPY

OIPE JC53
APR 19 2004
PATENT & TRADEMARK OFFICE

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	A1.	2002/0049307 A1	4/25/2002	Aebersold et al.	530	409	10/18/2001
	A2.	6,309,888	10/30/2001	Holvoet at al.	436	71	
	A3.	5,962,245	10/5/1999	Li et al.	435	18	
	A4.	5,601,985	2/11/1997	Trojanowski et al.	435	7.1	
	A5.	5,980,929	11/9/1999	de Juan, Jr.	424	427	
	A6.	5,710,008	1/20/1998	Jackowski	435	7.4	
	A7.	5,227,307	7/13/1993	Bar-Or et al.	436,	63	
	A8.	6,475,743	11/5/2002	Bar-Or et al.	435	7.1	
	A9.	6,492,179	12/10/2002	Bar-Or et al.	436	74	
	A10.	6,121,003	9/19/2000	Vanmechelen et al.	435	7.1	
	A11.	6,210,976	4/3/2001	Sabbadini	436	518	
	A12.	5,914,242	6/22/1999	Honkanen et al.	435	7.71	
	A13.	6,579,687	6/17/2003	Buechler et al.	435	7.92	
	A14.	5,947,124	9/7/1999	Buechler et al.	128	898	
	A15.	2003/0109420 A1	6/12/2003	Valkirs et al.	514	2	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	A16.	WO 93/08302	4/29/1993	PCT				
	A17.	EP 0 616 032 A2	9/21/1994	EPO				
	A18.	WO 94/13795	6/23/1994	PCT				
	A19.	WO 95/17429	6/29/1995	PCT				
	A20.	EP 0 526 150 B1	6/12/1996	EPO			X (abstract only)	
	A21.	WO 96/34977 A1	11/7/1996	PCT			(abstract only)	
	A22.	EP 0 823 943 B1	7/28/1999	EPO			X (abstract only)	
	A23.	WO 99/38012	7/29/1999	PCT				
	A24.	WO 00/20840	4/13/2000	PCT				
	A25.	WO 00/20454	4/13/2000	PCT				
	A26.	WO 00/14546	3/16/2000	PCT				
	A27.	JP 2001 258593 A2	9/25/2001	Japan			X (abstract only)	
	A28.	WO 01/71024 A1	9/27/2001	PCT			(abstract only)	
	A29.	AU 142741 A5	10/3/2001	Australia			(abstract only)	
	A30.	WO 02/089656	11/14/2002	PCT				
	A31.	WO 02/16947	2/28/2002	PCT				

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

	A32.	WO 02/066988	8/29/2002	PCT				
	A33.	WO 03/025571	3/27/2003	PCT				
	A34.	WO 03/00182	1/3/2003	PCT				
	A35.	WO 03/058249	7/17/203	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	A36.	Adamcova et al., *Physiol. Res.* 1999, **48**:235-247
	A37.	Andreason et al., *Acta Neurol. Scand. Suppl.* 2003, **179**:47-51, **Abstract only**, from PubMed - PMID:12603251
	A38.	Antipenko et al., *Vopr Med Khim* 1981, **27**(4):492-5, **Abstract only**, from PubMed - PMID:6270907
	A39.	Atar et al., *Ugeskr Laeger* 2003, **165**(2):116-20, **Abstract only**, from PubMed - PMID:12553091
	A40.	Bartel et al., *Biomed Biochim Acta* 1989, **48**(2-3):S108-13, **Abstract only**, from PubMed - PMID:2525030
	A41.	Blennow et al., *Mol Neurobiol* 2001, **24**(1-3), **Abstract only**, from PubMed - PMID:11831556
	A42.	Borutaite et al., *J Mol Cell Cardiol* 1996, **28**(10):2195-2201, **Abstract only**, from PubMed - PMID:8930814
	A43.	Brennan et al., *Biochim Biophys Acta* 1999, **1443**(1-2):321-326, **Abstract only**, from PubMed - PMID:10446380
	A44.	Dalrymple et al., *J Mol Neurosci* 2002, **19**(3):295-299, **Abstract only**, from PubMed - PMID:12540055
	A45.	Eikelenboom et al., *Trends Pharmacol. Sci.* 1994, **15**:447-450
	A46.	England et al., *Biomed Biochim Acta* 1987, **46**(5):369-380, **Abstract only**, from PubMed - PMID:2822035
	A47.	Fath et al., *J Neurosci* 2002, **22**:2977-9741, **Abstract only**, from PubMed - PMID:12427828
	A48.	Goedert et al., *Biochem J* 1994, **301**(Pt 3):871-877, **Abstract only**, from PubMed - PMID:7519852
	A49.	Hesse et al., *Neurosicence Letters* 2001, **297**:187-190
	A50.	Ingelson et al., *Dement. Geriatr Cogn. Disord*, 1999, **10**:442-445

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

	A51.	Jaquet et al., *Eur J Biochem* 1995, **231**(2):486-490, **Abstract only**, from PubMed - PMID:7635159
	A52.	Krause et al., *Gen Physiol Biophys* 1984, **3**:193-199, **Abstract only**, from PubMed - PMID:6479578
	A53.	Labugger et al., *Circulation* 2000, **102**:1221-1226
	A54.	Li et al., *Am. J. Physiol.* 1997, **272**:H360-H370
	A55.	Lim et al., *Analytical Bioochemistry* 2001, ***295:45-56***
	A56.	Lindhout et al., *Biochemistry* 2002, **41**(23):7267-7274, **Abstract only**
	A57.	Magrez et al., *www.currentdrugdiscovery.com,* September 2002, pp.23-27
	A58.	McDonough et al., *Circulation Research* 1999, **84**:9-20
	A59.	Moritz et al., *J Biol Chem* 2001, **276**(11):8244-8253, **Abstract only**, from PubMed - PMID:11098061
	A60.	Opie et al., *Jpn Circ J* 1978, **42**(11):1223-1247, **Abstract only**, from PubMed - PMID:34741
	A61.	Parnetti et al., *Neurol Sci* 2001, **22**(1):77-78, **Abstract only**, from PubMed - PMID:11487210
	A62.	Reimenschneider et al., *Mol Psychiatry* 2003, **8**(3):343-347, **Abstract only**, from PubMed - PMID:12660807
	A63.	Sang et al., *Neurosci Lett* 2001, **312**(3):141-144, **Abstract only**, from PubMed - PMID:11602330
	A64.	Schmidtmann et al., *FEBS Lett* 2002, **513**(2):389-293, **Abstract only**, from PubMed - PMID:11904166
	A65.	Sjogren et al., *J Neurol Neurosurg Psychiatry* 2001, **70**(5):624-630, **Abstract only**, from PubMed - PMID:11309456
	A66.	Teunissen et al., *Neurobiology of Aging* 2002, **23**:485-508
	A67.	Togawa et al., *Biochem Biophys Res Commun* 2000, **277**(3):668-674, **Abstract only**, from PubMed - PMID:11062011
	A68.	Vandermeeren et al., *J. Neurochem* 1993, **61**(5):1828-1834, **Abstract only**, from PubMed - PMID:8228996
	A69.	Van Everbroeck et al., *J Neurol Neurosurg Psychiatry* 2002, **73**(1):79-81, **Abstract only**, from PubMed - PMID:12082054
	A70.	Vanmechelen et al., *Neurosci Lett* 2000, **285**(1):49-52, **Abstract only**, from PubMed - PMID:10788705
	A71.	Ward et al., *J Biol Chem*, August 30, 2002 {epub ahead of print}, **Abstract only**, from PubMed - PMID:12207022

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-81	SERIAL NO. 10/680,935
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.	
	FILING DATE October 2, 2003	GROUP ART

	A72.	Westwood et al., *Biochem.* 198, **197**:185-193

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DMI BioSciences Inc.
3601 South Clarkson Street #420
Englewood, CO 80110-3944
Phone (303) 789-1929
Fax (303) 789-0510

OIPE
APR 19 2004
PATENT & TRADEMARK OFFICE

Fax

To:	Wannell Crook	**From:**	Kellie Hudnut
Fax:	303-663-9552	**Pages:**	14
Phone:	303-663-0788	**Date:**	8/7/03
Re:		**CC:**	

☐ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

Here is the first of the articles that you requested.

Kellie Hudnut

THE INFORMATION TRANSMITTED IS CONFIDENTIAL AND MAY CONTAIN CONFIDENTIAL AND/OR PRIVILEGED INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR COMPANY NAMED ABOVE. If the reader is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution, copying of this communication, or taking any action based upon this information is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone, so that we may arrange for the return of the original message. Thank you

BEST AVAILABLE COPY